Citadel Advisors
RLYB icon

Citadel Advisors’s Rallybio RLYB Stock Holding History

Citadel Advisors’s Portfolio RLYB Stock Details RLYB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178K Sell
19,886
-11,844
-37% -$81K ﹤0.01% 11524
2025
Q4 		$174K Sell
31,730
-23,108
-42% -$119K ﹤0.01% 11160
2025
Q3 		$219K Buy
54,838
+46,727
+576% +$196K ﹤0.01% 11076
2025
Q2 		$21.9K Buy
8,111
+1,510
+23% +$4K ﹤0.01% 12085
2025
Q1 		$34.6K Buy
+6,601
New +$41.7K ﹤0.01% 12680
2024
Q3 		– Sell
-35,000
Closed -$375K – 15081
2024
Q2 		$375K Sell
35,000
-14,958
-30% -$203K ﹤0.01% 8649
2024
Q1 		$739K Buy
49,958
+10,150
+25% +$141K ﹤0.01% 7549
2023
Q4 		$761K Buy
39,808
+4,563
+13% +$112K ﹤0.01% 7229
2023
Q3 		$950K Sell
35,245
-1,676
-5% -$72.6K ﹤0.01% 6659
2023
Q2 		$1.67M Sell
36,921
-7,244
-16% -$355K ﹤0.01% 5479
2023
Q1 		$2.02M Sell
44,165
-7
-0% -$362 ﹤0.01% 5351
2022
Q4 		$2.32M Buy
+44,172
New +$2.61M ﹤0.01% 5206

Other funds holding RLYB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors's RLYB Position: Q1 2026 in Review

Citadel Advisors reduced its Rallybio (RLYB) stake by 37% in Q1 2026, selling an estimated $81K and leaving 19,886 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #11524.

Citadel Advisors first reported a position in RLYB in Q4 2022 and has held it in 12 quarters since. The position peaked at $2.32M in Q4 2022. 38 funds tracked by Wall St. Rank hold RLYB as of Q1 2026.

  • Citadel Advisors held 19,886 shares of Rallybio worth $178K as of Q1 2026.
  • Citadel Advisors sold 11,844 Rallybio shares in Q1 2026, an estimated $81K.
  • Rallybio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11524 holding.
  • Citadel Advisors first reported a position in Rallybio in Q4 2022 and has held it in 12 quarters since.
  • Citadel Advisors's Rallybio position peaked at $2.32M in Q4 2022.
  • 38 funds tracked by Wall St. Rank held Rallybio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.